“Gene therapy for hemophilia A with the use of lentiviral vector-transduced autologous HSCs resulted in stable factor VIII expression, with factor VIII activity correlating to vector copy number in ...

Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization -- -- Adds novel, high-capacity, local ...

OXB to present at the Leerink Partners Global Healthcare Conference Oxford, UK – 26 February 2025: OXB (LSE: OXB), a global ...

The most common form of hereditary deafness in humans is caused by mutations in the GJB2 gene, which encodes the gap junction protein connexin 26. That regulates the transport of potassium and ...

The Global Viral Vector Market was valued at approximately USD 3.10 billion in 2022 and is projected to grow at a robust CAGR of more than 11.5% during the forecast period 2023-2030. Read the Market ...

One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience ... adeno-associated virus (AAV), adenovirus, and other viral vector types. OXB’s world-class ...

AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...

The AAV Innovation Summit 2025, hosted by Form Bio, will bring together top experts in gene therapy to discuss the latest advancements in adeno-associated virus (AAV) therapeutics. The event, set for ...

Bengaluru (Karnataka) [India], February 17: JAIN (Deemed-to-be University), a leader in innovative education, has launched the Bachelor’s in Occupational Therapy (BOT) program at its School of Allied ...

he said he became convinced that Kaspar’s gene therapy was the answer. Carbona remade BioLife into AveXis: Av for adeno-associated virus serotype 9, the engine of Kaspar’s drug; ve for vector ...

The team notes that different forms of SCN1B gene expression may result in different outcomes for the therapy. However, the proof-of-concept is the first step toward a gene replacement therapy for ...